Clinical trials: Locally Advanced Tumors
Cervical Cancer
Spatially Fractionated Radiation Therapy for Locally Advanced Cervical Cancer
This randomized clinical trial will evaluate whether adding spatially fractionated radiation therapy (SFRT) to definitive chemoradiotherapy improves outcomes in patients with locally advanced cervical cancer.
- Trial name
- SFRT-LACC (NCT07781475)
- Testing
- Spatially Fractionated Radiation Therapy, standard of care
- Where
- China
- Volunteers
- 126 people
- Sponsor
- The University of Hong Kong-Shenzhen Hospital
Carcinoma, Non-Small-Cell Lung
Phase II Safety and Tolerability Trial With Nab-Paclitaxel Plus Carboplatin Followed by Nab-Paclitaxel for First Line Treatment of NSCLC Subjects With ECOG PS 2
4 cycles of induction treatment with nab-paclitaxel and carboplatin followed by nab-paclitaxel monotherapy for those subjects who are progression free at the end of 4 cycles.
- Trial name
- AboundPS2 (NCT02289456)
- Testing
- nab-Paclitaxel, Carboplatin
- Where
- 8 sites in United States
- Volunteers
- 40 people
- Sponsor
- Celgene
Locally Advanced Solid Tumor, Metastatic Solid Tumor
HM95573 in Combination With Either Cobimetinib or Cetuximab in Patients With Locally Advanced or Metastatic Solid Tumors
This study evaluates the safety, tolerability and pharmacokinetics of HM95573 In combination with either cobimetinib or cetuximab in patients with locally advanced or metastatic solid tumors.
- Trial name
- NCT03284502
- Testing
- HM95573, cobimetinib, HM95573, cetuximab
- Where
- 9 sites in South Korea
- Volunteers
- 148 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Squamous Cell Carcinoma of Larynx
Study of a Pembrolizumab-based Organ Preservation Strategy for Locally Advanced Larynx Cancers
This a prospective, single-arm, multi-institutional, open label, phase 2 trial evaluating the effects of induction chemo-immunotherapy, followed by radioimmunotherapy, followed by consolidation immunotherapy in patients with…
- Trial name
- SMART-KEY (NCT04943445)
- Testing
- carboplatin AUC of 6, paclitaxel 175 mg/m2, and pembrolizumab 200 mg, i.v. on day 1, every 21 days for 3 cycles, Concurrent radio-immunotherapy: radiation therapy given concurrently with pembrolizumab 200 mg i.v. on day 1, every 21 days for 3 cycles., Consolidation immunotherapy: pembrolizumab 200 mg i.v. on day 1, every 21 days for 11 doses.
- Where
- 9 sites in Brazil
- Volunteers
- 43 people
- Sponsor
- Latin American Cooperative Oncology Group
ESCC, TAS 102
TAS-102 Plus Radiotherapy in Elderly ESCC
This study is a single-arm, multicenter clinical trial evaluating the efficacy and safety of radiotherapy combined with TAS-102 monotherapy in elderly patients with locally advanced esophageal cancer.
- Conditions
- ESCC, TAS 102, Radiotherapy
- Trial name
- NCT07196345
- Testing
- TAS-102, Radiotherapy
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Qianfoshan Hospital
Colorectal Neoplasms
Multi-omics Model Predicts Efficacy of Preoperative Neoadjuvant Chemoradiotherapy Combined PD-1 Antibody Therapy for Locally Advanced Rectal Cancer
The purpose of this clinical research is to establish a multi-omics model based on genomics，transcriptomics，gut microbiota in predicting pathologic response after neoadjuvant chemoradiotherapy combined PD-1 antibody given to…
- Trial name
- NCT05368051
- Testing
- long course radiotherapy + capecitabine + PD-1 monoclonal antibody
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Beijing Friendship Hospital
Pancreatic Cancer
Safety and Efficacy Study of 90Y-hPAM4 at Different Doses
Safety study to determine highest dose of 90Y-hPAM4 can be safety administered
- Trial name
- NCT00597129
- Testing
- 90Y-hPAM4
- Where
- 4 sites in United States
- Volunteers
- 21 people
- Sponsor
- Gilead Sciences
Gastric Cancer
DC-CIK In Combination With Chemotherapy ( Gio / Oxaliplatin or Cisplatin ) Versus First-line Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma Randomized Controlled Phase II Clinical Study of Treatment
This study evaluates the therapeutic effects of autologous dendritic cells co-cultured with cytokine-induced killer cells (DC-CIK) combined with S-1 ((Tegafur, Gimeracil, and Oteracil Potassium) and oxaliplatin adjuvant…
- Trial name
- NCT02504229
- Testing
- autologous dendritic cells co-cultured with cytokine-induced killer cells, Gimeracil and Oteracil Porassium Capsules, Oxaliplatin
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Beijing Biohealthcare Biotechnology Co.,Ltd
Breast Cancer
Safety Study of Pertuzumab (in Combination With Trastuzumab and Docetaxel) in Indian Participants With Breast Cancer
This is a Phase 4, single-arm, open-label, multicenter study to assess the safety and efficacy of pertuzumab in combination with trastuzumab and docetaxel for the treatment of participants with human epidermal growth factor…
- Trial name
- NCT02445586
- Testing
- Docetaxel, Pertuzumab, Trastuzumab
- Where
- 9 sites in India
- Volunteers
- 52 people
- Sponsor
- Hoffmann-La Roche
Cancer
A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
This open-label, Phase Ib study that has six treatment arms is designed to assess the safety, pharmacology and preliminary efficacy of atezolizumab (MPDL3280A; an engineered anti-programmed death-ligand 1 [PDL1] antibody)…
- Trial name
- NCT01633970
- Testing
- 5-FU, Atezolizumab, Bevacizumab
- Where
- 11 sites in United States
- Volunteers
- 240 people
- Sponsor
- Genentech, Inc.
Malignant Neoplasm
Cixutumumab and Temsirolimus in Treating Patients With Locally Advanced or Metastatic Cancer
This phase I trial studies the side effects and best dose of cixutumumab and temsirolimus in treating patients with locally advanced or metastatic cancer.
- Trial name
- NCT00678769
- Testing
- Cixutumumab, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 2 sites in United States
- Volunteers
- 72 people
- Sponsor
- National Cancer Institute (NCI)
Locally Advanced Cervical Cancer
Curcumin Supplementation in Cervical Cancer
Brief Summary. The goal of this pilot study is to learn about the effect of curcumin supplementation in locally advanced cervical cancer patients.
- Trial name
- NCT06080841
- Testing
- Curcumin, Curcumin + Piperine
- Where
- Mexico
- Volunteers
- 30 people
- Sponsor
- National Institute of Cancerología
Nasopharyngeal Cancer
Whole-Body 18F-FDG PET in Induction Chemotherapeutic Response for Advanced NPC Patients
18F-FDG PET, a whole-body imaging technology based on glucose metabolism, can effectively detect subclinical and clinical therapeutic responses at stages that are earlier than those detected by conventional approaches.
- Trial name
- NCT00304694
- Where
- Taiwan
- Volunteers
- 50 people
- Sponsor
- National Taiwan University Hospital
Prostate Cancer
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment of metastases-free survival…
- Trial name
- EvoPAR-PR02 (NCT06952803)
- Testing
- Saruparib, Abiraterone + Prednisolone/Prednisone, Androgen Deprivation Therapy (ADT)
- Where
- 346 sites in United States, Argentina and 26 more
- Volunteers
- 700 people
- Sponsor
- AstraZeneca
Pancreatic Cancer
SOM 230 and Gemcitabine in Advanced Pancreatic Cancer
The goal of this clinical research study is to learn if the study drug SOM 230 in addition to standard therapy of gemcitabine can shrink or slow the growth of pancreatic cancer.
- Trial name
- NCT01385956
- Testing
- SOM 230 LAR, Gemcitabine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
NSCLC (Advanced Non-small Cell Lung Cancer)
Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK201 for Injection in Combination With Ivonescimab Injection in sqNSCLC Participants.
This is an open-label, multicenter, Phase II clinical study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of ALK201 for Injection combined with Ivonescimab Injection in adult patients with…
- Trial name
- NCT07742956
- Testing
- ALK201 for injection, Ivonescimab Injection
- Volunteers
- 156 people
- Sponsor
- Shanghai Allink Biotherapeutics Co., Ltd.
Rectal Cancer, Advanced Cancer
Complete Versus Partial Preservation of Denonvilliers' Fascia on Urogenital Function in Locally Advanced Rectal Cancer
Total mesorectal resection (TME) is the standard surgical method for locally advanced rectal cancer, which significantly reduces the local recurrence rate. However, the incidence of urogenital dysfunction is higher.
- Trial name
- NCT04672603
- Testing
- Complete Preservation of Denonvilliers' Fascia
- Where
- China
- Volunteers
- 214 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Treatment
Stereotactic Radiotherapy in Locally Advanced Pancreatic Cancer With Different Biological Effective Doses
The aim of this study is to compare the safety and efficacy of SBRT in LAPC with different biological effective dose (BED) (<70Gy Vs.>70Gy ) , to identify a dose range that could achieve better survival benefit and minimize the…
- Trial name
- NCT04603586
- Testing
- SBRT, Chemotherapy
- Where
- 2 sites in China
- Volunteers
- 119 people
- Sponsor
- Changhai Hospital
Colorectal Adenocarcinoma
Oncological Impact of Lateral Nodes in Rectal Cancer
The combination of neoadjuvant chemoradiotherapy (CRT) and total mesorectal excision (TME) is considered the standard treatment for locally advanced rectal cancer in the western world.
- Trial name
- I-ONARC (NCT05592873)
- Testing
- Neoadjuvant chemoradiotherapy (CRT)
- Volunteers
- 317 people
- Sponsor
- Niguarda Hospital
Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
The NEO-811-101 study is an open-label, first-in-human, Phase 1/2 dose escalation and expansion study testing NEO-811, an ARNT molecular glue degrader, in subjects with locally advanced or metastatic non-resectable clear cell…
- Conditions
- Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma, RCC, Clear Cell Renal Cell Carcinoma Metastatic
- Trial name
- NCT07300241
- Testing
- NEO-811
- Where
- 16 sites in United States
- Volunteers
- 30 people
- Sponsor
- Neomorph, Inc
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.